Discovery of Macrocycle-Based HPK1 Inhibitors for T-Cell-Based Immunotherapy.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of medicinal chemistry"
DOI: 10.1021/acs.jmedchem.2c01551
Abstract: Hematopoietic progenitor kinase 1 (HPK1) is a negative regulator of T-cell activation, and targeting HPK1 is considered a promising strategy for improving responses to antitumor immune therapies. The biggest challenge of HPK1 inhibitor design is… read more here.
Keywords: hpk1 inhibitors; based hpk1; discovery macrocycle; macrocycle based ... See more keywords